Abstract
Chronic migraine (CM) represents an important medical issue, due to morbidity, high disability, presence of comorbidities, and medication overuse (MO). The prophylaxis of CM has not been extensively explored so far. Patients with CM are often treated with two or more compounds, although there is no clear evidence that polytherapy may be superior to monotherapy. We evaluated the percentage of prescription of polytherapy for the prophylaxis of CM in a clinical sample. We examined the charts of 98 CM patients admitted to our Headache Center for inpatient withdrawal program to stop MO. Results showed that only one drug for prophylaxis was prescribed in 20.4% cases, two or more drugs in 79.6%, with 63.3% of the total sample falling in the group “true polytherapy”, i.e. all the drugs prescribed on daily basis were given to treat CM, and not only to treat concomitant conditions. In more than 60% cases a combination of drugs indicated for migraine prophylaxis and drugs only indicated for other conditions (mainly for psychiatric disorders) was prescribed. Our survey indicates that polytherapy may be rather common in CM, and suggests that comorbidities may strongly influence treatment choices.
References
Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559–566
Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, Diener HC, Limmroth V (2004) Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62(5):788–790
Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22(3):269–276
Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, Lipton R (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609
Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9(4):391–401
D’Amico D, Usai S, Grazzi L, Rigamonti A, Solari A, Leone M, Bussone G (2003) Quality of life and disability in primary chronic daily headaches. Neurol Sci 24:S97–S100
D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G (2005) Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache 45:553–560
Lanteri-Minet M, Chautard MH, Lucas C (2005) Chronic migraine and medication overuse: results of Framig 3, a French population-based survey carried out according to the 2004 IHS classification. Neurology Suppl 2:A132
Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1–96
Headache Classification (2004) Subcommittee of the International Headache Society The international classification of headache disorders. Cephalalgia 24:S1–S160
Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746
Silberstein SD, Lipton RB, Sliwinski M (1996) Classification of daily and near-daily headaches. Neurology 47:871–8751
Mathew NT (2009) Dynamic optimization of chronic migraine treatment: current and future options. Neurology 72(Suppl 5):S14–S20
D’Amico D (2010) Pharmacological prophylaxis of chronic migraine. A review of double-blind placebo-controlled trials. Neurol Sci 31(Suppl 1):S23–S28
Krymchantowski AV, Silva MT, Barbosa JS, Alves LA (2002) Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 42:510–514
Krymchantowski AV, Hampshire F (2004) Polytherapy in migraine prevention. Clinical experience with the combination of a tricyclic antidepressant plus a calcium channel blocker. Headache 44:499–500
Pascual J, Rivas MT, Leira R (2007) Testing the combination betablocker plus topiramate in refractory migraine. Acta Neurol Scand 115:81–83
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS, European Federation of Neurological Societies (2009) EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol 16(9):968–981
Wiendels NJ, van Haestregt A, Knuistingh Neven A, Spinhoven P, Zitman FG, Assendelft WJ, Ferrari MD (2006) Chronic frequent headache in the general population: comorbidity and quality of life. J Neurol Neurosurg Psychiatry 81:428–432
Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemogaphic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428–432
Conflict of interest
The authors declare that there is no actual or potential conflict of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
D’Amico, D., Curone, M., Tullo, V. et al. Polytherapy for the prophylaxis of chronic migraine: an Italian survey. Neurol Sci 32 (Suppl 1), 185–188 (2011). https://doi.org/10.1007/s10072-011-0521-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-011-0521-8